Evaluation of quercetin as a potential drug in osteosarcoma treatment

Kersten Berndt, Carmen Campanile, Roman Muff, Emanuel Strehler, Walter Born, Bruno Fuchs

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Background: Osteosarcoma is the most common malignant bone tumor in children and young adults. Since the introduction of chemotherapy, the 5-year survival rate of patients with non-metastatic osteosarcoma is ∼70%. The main problems in osteosarcoma therapy are the occurrence of metastases, severe side-effects and chemoresistance. Antiproliferative and apoptotic effects of quercetin were shown in several types of cancers, including breast cancer and lung carcinoma. Materials and Methods: The present study investigates the cytotoxic potential of quercetin, a dietary flavonoid, in a highly metastasizing human osteosarcoma cell line, 143B. Results: We found that quercetin induces growth inhibition, G2/M phase arrest, and apoptosis in the 143B osteosarcoma cell line. We also observed impaired adhesion and migratory potential after the addition of quercetin. Conclusion: Since quercetin has already been shown to have low side effects in a clinical phase I trial in advanced cancer patients, this compound may have considerable potential for osteosarcoma treatment.

Original languageEnglish (US)
Pages (from-to)1297-1306
Number of pages10
JournalAnticancer research
Volume33
Issue number4
StatePublished - Apr 1 2013

Keywords

  • 143B cells
  • Apoptosis
  • Cell-cycle arrest
  • Migration
  • Osteosarcoma
  • Quercetin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Evaluation of quercetin as a potential drug in osteosarcoma treatment'. Together they form a unique fingerprint.

  • Cite this

    Berndt, K., Campanile, C., Muff, R., Strehler, E., Born, W., & Fuchs, B. (2013). Evaluation of quercetin as a potential drug in osteosarcoma treatment. Anticancer research, 33(4), 1297-1306.